Collegium (COLL) Q2 2025: Jornay PM Drives 23% Rx Growth, Powering Guidance Raise and Portfolio Durability
Collegium’s Q2 saw Jornay PM, ADHD therapy, accelerate prescription growth and push portfolio revenues to new highs, prompting a guidance raise and reinforcing pain franchise durability. Management is leveraging targeted commercial investments and disciplined capital deployment to drive both near-term growth and longer-term diversification. The company’s posture on business development, cash deployment, and generic risk management signals a strategic pivot toward a broader biopharma platform.
Summary
- Jornay PM Commercial Expansion: ADHD franchise momentum is outpacing expectations as prescriber base and patient mix broaden.
- Pain Portfolio Stability: Core pain medicines deliver consistent growth and cash flow, supporting capital returns and future M&A.
- Capital Flexibility for Diversification: Strong cash generation and new buyback authorization set up optionality for external growth.
Performance Analysis
Collegium delivered 29% year-over-year revenue growth in Q2, led by a breakout performance from Jornay PM, its differentiated ADHD therapy, and solid expansion across its legacy pain portfolio. Jornay PM revenue reached a quarterly record, with prescriptions up 23% and market share in the long-acting branded methylphenidate category climbing to 23%, a 7.6-point gain year over year. The pain franchise, comprising Belbuca, Xtampza ER, and Nucynta ER, posted 7% revenue growth, with all three medicines contributing and reinforcing the franchise’s durability narrative.
Operating cash flow was robust at $72.4 million, enabling aggressive capital deployment—$25 million in share repurchases and $16.1 million in debt repayment. Operating expenses rose sharply, reflecting the full ramp of Jornay commercialization, including a sales force expansion and new marketing campaigns. Despite the margin impact, adjusted EBITDA still grew 9% year over year, demonstrating underlying leverage in the model as top-line growth outpaces cost escalation.
- Jornay PM Prescription Acceleration: 23% Rx growth and broadened prescriber base to over 26,000, with adult patient growth outpacing pediatric.
- Pain Portfolio Cash Engine: Pain products generated $155.4 million in revenue, providing stable cash flow for reinvestment and capital returns.
- Cost Investment for Growth: Operating expenses up over 100% YoY on a non-GAAP basis, primarily tied to Jornay PM commercial build-out.
Management’s raised guidance for both revenue and EBITDA signals confidence in the execution of its ADHD and pain strategies, with an eye toward further business development and portfolio expansion as cash builds.
Executive Commentary
"We are well positioned for our next phase of growth, and I am confident in our ability to deliver on our financial and strategic commitments. In just a short period of time, we have integrated Journée into our portfolio of differentiated medicines, expanded the size and scope of the collegium team, and established a new growth platform for our company."
Vikram Karnani, President and Chief Executive Officer
"We delivered strong financial results in the second quarter, growing revenue 29% and adjusted EBITDA 9% year over year, while making targeted investments to drive continued growth in JornATM. We generated robust operating cash flows of $72.4 million and executed our capital deployment priorities, including returning $25 million of value to shareholders through share repurchases and repaying $16.1 million of debt."
Colleen Tupper, Chief Financial Officer
Strategic Positioning
1. ADHD Franchise Momentum and Leverage
Jornay PM, once-daily evening-dosed ADHD stimulant, is capturing share through both prescriber expansion and increased adult patient penetration. The sales force expansion (to 180 representatives) and targeted HCP and patient marketing are driving both breadth and depth, with 2,700 new prescribers writing scripts in Q2. Adult prescriptions now represent 20% of volume, growing faster than pediatric, and management sees further upside from closing the awareness gap among HCPs regarding adult morning efficacy needs.
2. Pain Portfolio as Durable Cash Generator
Collegium’s pain portfolio—anchored by Belbuca, Xtampza ER, and Nucynta ER—remains the financial backbone, comprising roughly half of the branded ER opioid market. Management emphasized exclusivity into 2027 and beyond, with no credible near-term generic threat due to regulatory, legal, and supply chain barriers. Stable investment and consistent commercial execution are expected to prolong the franchise’s cash generation well past current market expectations.
3. Capital Deployment and Shareholder Returns
Management’s approach to capital allocation is balanced between debt reduction, share repurchases, and external growth. A new $150 million buyback program (through 2026) underscores confidence in cash flow durability. Net leverage is targeted below 1.0x by year-end, with ongoing assessment of business development opportunities focused on leveraging existing commercial infrastructure in pain, ADHD, and psychiatry.
4. Business Development and Portfolio Diversification
Collegium is signaling a strategic pivot to a diversified biopharma platform, with management open to expanding beyond pain and CNS if the right commercial-stage or commercial-ready assets are available. The emphasis remains on financial discipline, margin protection, and leveraging commercial scale before moving into earlier-stage pipeline assets.
5. Commercial Execution and Seasonality
The company is targeting the critical back-to-school season for ADHD therapy adoption, with new digital and social campaigns aimed at both prescribers and caregivers. Management expects full impact from the expanded sales force and marketing investments to materialize in 2026 and beyond, but early indicators are positive for near-term acceleration.
Key Considerations
Collegium’s Q2 results highlight a business at an inflection point, with strong execution on both organic and inorganic growth levers and a clear focus on sustainable cash generation.
Key Considerations:
- Jornay PM Awareness Gap: Management sees significant headroom to further penetrate the adult ADHD market and close the awareness gap among HCPs.
- Pain Portfolio Exclusivity: Legal and supply chain barriers are likely to delay generic entry, supporting stable revenues and funding future growth.
- Cost Structure Dynamics: Elevated operating expenses reflect front-loaded investment in Jornay PM, with expectations for expense moderation in H2.
- Capital Return Optionality: Strong cash flow and low leverage enable both opportunistic buybacks and potential M&A without sacrificing balance sheet strength.
- Business Development Discipline: Management remains focused on commercial-stage assets that fit existing infrastructure, resisting the temptation to chase non-core or early-stage pipeline deals.
Risks
Key risks include: potential for slower-than-expected prescription growth in Jornay PM if HCP and patient awareness campaigns underdeliver, unexpected generic entry in the pain portfolio despite current barriers, and execution risk around future business development deals. Elevated operating expenses could pressure margins if top-line momentum slows. Investors should also monitor regulatory and payer dynamics in both ADHD and pain management markets, as well as evolving public policy toward controlled substances.
Forward Outlook
For Q3 2025, Collegium guided to:
- Continued top-line acceleration from Jornay PM, with seasonality expected to drive further Rx growth.
- Stable pain portfolio performance with no anticipated generic disruption in the near term.
For full-year 2025, management raised guidance:
- Total product revenues of $745 to $760 million, up $10 million from prior guidance.
- Jornay PM revenue of $140 to $145 million, up from at least $135 million previously.
- Adjusted EBITDA of $440 to $455 million, a $5 million increase from prior guidance.
Management cited several drivers for the outlook:
- Back-to-school seasonality and expanded sales force impact for Jornay PM.
- Ongoing cash flow generation and operating expense discipline in H2.
Takeaways
Collegium’s execution in Q2 2025 reinforces its dual-engine growth model, with Jornay PM’s rapid commercial ramp complementing the resilient pain franchise. The company’s capital deployment and business development discipline provide a strong foundation for future diversification and growth.
- Jornay PM’s share gains and prescriber expansion are driving outsized ADHD growth, with further upside as adult patient awareness improves.
- Pain portfolio durability is underappreciated, with no credible generic threat on the horizon, supporting stable cash generation for capital returns and M&A.
- Investors should watch for continued prescription momentum into the critical back-to-school season, as well as updates on business development and capital allocation in coming quarters.
Conclusion
Collegium’s Q2 showcased accelerating ADHD franchise growth, pain portfolio resilience, and a disciplined capital allocation framework, all of which underpin its raised guidance and strategic confidence. The company is executing on both organic and inorganic levers, with a clear path to broader biopharma diversification and value creation.
Industry Read-Through
Collegium’s results signal that differentiated ADHD therapies with strong payer access and targeted commercial investment can outgrow the broader stimulant market, especially as adult diagnosis and treatment expand. The durability of branded pain franchises with legal and supply chain barriers highlights the value of exclusivity in the opioid space, even as broader industry sentiment remains cautious. For specialty pharma peers, the quarter underscores the importance of disciplined capital deployment, M&A selectivity, and leveraging commercial infrastructure to maximize both organic and inorganic growth opportunities.